NURS 6521 Exam 1 V1 | NURS 6521
Advanced Pharmacology | Actual Q&A
with Rationale (NURS6521 Exam 1) |
Walden University
1. When considering the pharmacokinetics of a drug, which process is primarily responsible
for the conversion of a drug into a more water-soluble form that can be excreted?
A. Metabolism
B. Distribution
C. Absorption
D. Excretion
Answer: A
Rationale: Metabolism, also known as biotransformation, is the process by which the body
chemically changes the drug structure. This primarily occurs in the liver via enzymes like
the cytochrome P450 system. The main goal is to make the drug more polar or water-
soluble so that the kidneys can effectively remove it from the body.
2. An elderly patient is prescribed a lipid-soluble medication. How does the physiological
change in body composition in geriatric patients affect the distribution of this drug?
A. Increased total body water reducing concentration
B. Decreased volume of distribution and rapid clearance
,C. Decreased total body fat leading to toxicity
D. Increased volume of distribution and prolonged half-life
Answer: D
Rationale: Geriatric patients typically experience an increase in total body fat and a
decrease in total body water and lean muscle mass. Lipid-soluble drugs distribute into fatty
tissues, meaning an increase in fat leads to a larger volume of distribution. This causes the
drug to remain in the body longer, effectively prolonging the elimination half-life and
increasing the risk for accumulation.
3. The Nurse Practitioner is reviewing the clinical trial data for a new drug. In which phase of
clinical testing is the drug evaluated for its safety and dosage range in a small group of
healthy volunteers?
A. Phase II
B. Phase I
C. Phase III
D. Phase IV
Answer: B
Rationale: Phase I clinical trials are the first stage of testing in humans and involve a small
number of healthy volunteers. The primary focus of this phase is to evaluate the drug’s
safety, determine a safe dosage range, and identify side effects. It also provides preliminary
data on the drug’s pharmacokinetic properties before moving to larger patient populations.
, 4. A patient with chronic renal failure requires a dose adjustment for a medication primarily
excreted by the kidneys. Which laboratory value is the most reliable indicator for calculating
the required dose?
A. Creatinine Clearance
B. Serum Albumin
C. Blood Urea Nitrogen (BUN)
D. Alanine Aminotransferase (ALT)
Answer: A
Rationale: Creatinine clearance is the most accurate clinical measure of glomerular
filtration rate (GFR) and renal function. As renal function declines, the kidneys’ ability to
clear drugs decreases, leading to potential toxicity. Practitioners use the Cockcroft-Gault
equation to estimate this value and adjust drug dosages accordingly to ensure patient
safety.
5. Which schedule of controlled substances includes drugs with a high potential for abuse, no
currently accepted medical use in the United States, and a lack of accepted safety for use
under medical supervision?
A. Schedule II
B. Schedule I
C. Schedule III
D. Schedule IV
Advanced Pharmacology | Actual Q&A
with Rationale (NURS6521 Exam 1) |
Walden University
1. When considering the pharmacokinetics of a drug, which process is primarily responsible
for the conversion of a drug into a more water-soluble form that can be excreted?
A. Metabolism
B. Distribution
C. Absorption
D. Excretion
Answer: A
Rationale: Metabolism, also known as biotransformation, is the process by which the body
chemically changes the drug structure. This primarily occurs in the liver via enzymes like
the cytochrome P450 system. The main goal is to make the drug more polar or water-
soluble so that the kidneys can effectively remove it from the body.
2. An elderly patient is prescribed a lipid-soluble medication. How does the physiological
change in body composition in geriatric patients affect the distribution of this drug?
A. Increased total body water reducing concentration
B. Decreased volume of distribution and rapid clearance
,C. Decreased total body fat leading to toxicity
D. Increased volume of distribution and prolonged half-life
Answer: D
Rationale: Geriatric patients typically experience an increase in total body fat and a
decrease in total body water and lean muscle mass. Lipid-soluble drugs distribute into fatty
tissues, meaning an increase in fat leads to a larger volume of distribution. This causes the
drug to remain in the body longer, effectively prolonging the elimination half-life and
increasing the risk for accumulation.
3. The Nurse Practitioner is reviewing the clinical trial data for a new drug. In which phase of
clinical testing is the drug evaluated for its safety and dosage range in a small group of
healthy volunteers?
A. Phase II
B. Phase I
C. Phase III
D. Phase IV
Answer: B
Rationale: Phase I clinical trials are the first stage of testing in humans and involve a small
number of healthy volunteers. The primary focus of this phase is to evaluate the drug’s
safety, determine a safe dosage range, and identify side effects. It also provides preliminary
data on the drug’s pharmacokinetic properties before moving to larger patient populations.
, 4. A patient with chronic renal failure requires a dose adjustment for a medication primarily
excreted by the kidneys. Which laboratory value is the most reliable indicator for calculating
the required dose?
A. Creatinine Clearance
B. Serum Albumin
C. Blood Urea Nitrogen (BUN)
D. Alanine Aminotransferase (ALT)
Answer: A
Rationale: Creatinine clearance is the most accurate clinical measure of glomerular
filtration rate (GFR) and renal function. As renal function declines, the kidneys’ ability to
clear drugs decreases, leading to potential toxicity. Practitioners use the Cockcroft-Gault
equation to estimate this value and adjust drug dosages accordingly to ensure patient
safety.
5. Which schedule of controlled substances includes drugs with a high potential for abuse, no
currently accepted medical use in the United States, and a lack of accepted safety for use
under medical supervision?
A. Schedule II
B. Schedule I
C. Schedule III
D. Schedule IV
